The latest news for pharma industry insiders.

The Verseon CEO discusses how this advanced technology is helping to discover new drug candidates.

Investment is expected to bring approximately 1,000 new jobs at Novartis and 4,000 additional roles across the United States.

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK fusion-positive solid tumors.

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin by week 24.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses Juvena’s "pipeline in a product" JUV-161 and plans to broaden into other disease indications.

The latest news for pharma industry insiders.

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with participation from multiple other investors.

Davidi Vortman, CEO, UltraSight, discusses how AI-powered heart scan technology can help high-risk cardiovascular disease patients.

LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses how Takeda will ensure that diversity and inclusion remain a priority in its clinical trials moving forward.

The latest news for pharma industry insiders.

The company announced a new CFO along with the creation of a new role, chief medical officer.

PharmaLogic states that the acquisition of Agilera Pharma AS will place the company in a unique global role in radiopharmaceutical production and distribution.

As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.

Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was the largest immunotherapy study in patients with previously untreated, unresectable, or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

Brimochol PF, a combination of brimonidine and carbachol, was found to enhance depth of focus and visual acuity in clinical trials among patients with presbyopia.

The latest news for pharma industry insiders.

Amy Hessels, Bayer‘s vice president of marketing, talks about how to engage younger demographics and how the Your Decision campaign contributes to broader conversations about women's reproductive autonomy and healthcare access.

The survey also suggests that Medicaid is broadly popular amongst all Americans, regardless of political affiliation.

LaShell Robinson, head of global feasibility and trial equity at Takeda, identifies some of the key barriers in achieving representative clinical trials for psoriasis, and how they are overcoming them.

Hyfe’s CEO discusses the importance of DTx and how it can change the way certain conditions are treated.

“We’re going to tariff our pharmaceuticals, and once we do that, they are going to come rushing back into our country," President Donald J. Trump said during a Tuesday night dinner in Washington.

Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm autoimmune hemolytic anemia and IgG4-related disease.

Amy Hessels, vice president of marketing, Bayer, discusses how its Your Decision campaign tackles misinformation about reproductive health by providing the information to empower women to discuss options with healthcare providers.

The latest news for pharma industry insiders.